Skip to main content
S&P 5007,683.69-0.77%DOW51,481.51-0.67%NASDAQ26,820.38-0.92%BTC$83,274.00-1.39%ETH$2,680.04-0.13%GOLD$4,151.70-0.40%OIL$93.09+0.53%
Smart Investors Daily
ML

NASDAQ · MLYS

Mineralys Therapeutics, Inc.

Healthcare · Biotechnology

$25.63

Down-$0.23 (-0.89%)

Updated Sep 29, 2026, 5:08 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.39B
P/E ratio
-12.37
Dividend yield
0.00%
52-week range
$22.30 – $47.65
Volume
1.69M
Avg. volume
1.48M

Price performance · MLYS

MLYS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 28, 2026

MLYS closed at $25.63 after 20 trading sessions, down 0.16% for the selected period.

Last close
$25.63
Period change
-0.16%
Period low
$25.57
Period high
$31.12
Daily close
View OHLC price history
MLYS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 28, 2026$25.46$25.95$24.92$25.631.69M
Sep 25, 2026$26.55$26.70$25.21$25.861.19M
Sep 24, 2026$26.77$27.07$25.83$26.59895.4K
Sep 23, 2026$29.36$29.83$26.62$26.891.48M
Sep 22, 2026$28.63$29.55$28.37$29.40849.46K
Sep 21, 2026$28.19$28.44$27.90$28.31701.84K
Sep 18, 2026$27.77$28.13$27.38$28.023.79M
Sep 17, 2026$27.95$29.52$27.93$27.981.14M
Sep 16, 2026$28.98$29.085$27.33$27.541.42M
Sep 15, 2026$28.58$28.985$27.55$28.911.78M
Sep 14, 2026$28.14$29.61$27.89$28.951.19M
Sep 11, 2026$29.65$29.945$28.17$28.201.73M
Sep 10, 2026$30.04$30.57$29.20$29.30763.76K
Sep 9, 2026$30.87$31.99$30.43$30.502.05M
Sep 8, 2026$28.03$31.59$28.03$31.122.59M
Sep 4, 2026$28.00$28.35$27.395$28.21643.52K
Sep 3, 2026$29.15$29.40$27.715$28.271.33M
Sep 2, 2026$25.70$29.285$25.70$29.042.04M
Sep 1, 2026$25.47$26.33$24.98$25.57728.42K
Aug 31, 2026$25.42$25.95$25.06$25.671.08M

Latest MLYS news

The latest Smart Investors Daily articles mentioning MLYS.

Stock researchCompany · Overview

MLYS research

Overview

Company profile and research snapshot.

Company profile

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$52.00
Implied upside
—
Analysts
—
MLYS recent ratings
DateFirmRatingTarget
Apr 27, 2026TD CowenBuy—
Mar 13, 2026B of A SecuritiesBuy—
Dec 19, 2025StifelBuy—
Nov 12, 2025HC Wainwright & Co.Buy—
Nov 11, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 21, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award cov

Yahoo · Sep 9, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards coveri

Yahoo · Aug 26, 2026

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 202

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By